www.fdanews.com/articles/183294-cardio-indication-approved-for-diabetes-drug
Cardio Indication Approved for Diabetes Drug
August 30, 2017
The FDA has approved Novo Nordisk’s Victoza (liraglutide) as a type 2 diabetes drug that reduces the risk of heart attack and stroke.
The drug was approved by the FDA in 2010 for blood-sugar control. The latest approval adds its effect on cardiovascular risk to its benefits.
An injectable, Victoza is approved for adults with diabetes 2 or cardiovascular disease.